SLNCF — Silence Therapeutics Share News
0.000.00%
Last trade - 00:00- $902.88m
- $830.82m
- $0.56m
Silence Therapeutics - Holding(s) in Company
Brief: Silence Therapeutics Says First Patient Dosed In Gemini II Phase I Clinical Trial For SLN124
Silence Therapeutics - First patient dosed in GEMINI II
Brief: Silence Therapeutics Says Achieved Another Research Milestone Payment From Mallinckrodt Collaboration For Complement-Mediated Diseases
Silence Therapeutics - Silence Achieves Research Milestone Payment
Silence Therapeutics - Grant of Employee Options
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Silence Therapeutics - Purchase of ADS and PDMR Shareholding
Silence Therapeutics - Publication in Cardiovascular Research
Silence Therapeutics - Silence to Present at Virtual Needham Conference
Silence Therapeutics - Silence Therapeutics Publication of Annual Report
Brief: Silence Therapeutics FY Operating Loss 35.8 Mln Stg
Silence Therapeutics - Silence Reports Full-year 2020 Results
Silence Therapeutics - Block Listing Application
Silence Therapeutics - Silence presents at Barclays Healthcare Conference
Silence Therapeutics - Notice of Annual Results
Brief: Silence Therapeutics And Mallinckrodt Initiate Work On Third Target As Part Of Ongoing RNAi Research Collaboration
Silence Therapeutics - Silence & Mallinckrodt Initiate Work on 3rd Target